Drug Profile

TPIV 100

Alternative Names: H2NVAC; TPIV-100

Latest Information Update: 04 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mayo Clinic
Developer Marker Therapeutics Inc; Mayo Clinic
Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II HER2 positive breast cancer

Most Recent Events

31 May 2024 Adverse events data from a phase II trial in HER2-positive-breast-cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
02 Mar 2021 Phase-I/II development is ongoing in USA
20 Feb 2020 Phase-II clinical trials in HER2-positive-breast-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intradermal)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com